In 2016, a meta-analysis of 107 articles [50] was conducted to investigate AdipoQ levels in various malignancies and found that AdipoQ levels in certain cancers (including acute leukemia, multiple myeloma, breast cancer, colorectal cancer, and uterine cancer, endometrial cancer, prostate cancer, thyroid cancer, tongue cancer, and gastroesophageal cancer) were significantly reduced, while HCC was significantly higher than the CFC group. This evidence concerns the gene ADIPOQ and thyroid gland carcinoma.